K. Hori, Misa Hosoi, Kimiko Konishi, M. Hachisu, H. Tomioka, Michiho Sodenaga, Chiaki Hashimoto, Ouga Sasaki, Mioto Maedomari, Itsuku Suzuki, Masanori Tadokoro, Sachiko Tsukahara, Hiroyuki Kamatani, Masayuki Tani, Hiroaki Tanaka, Y. Kitajima, H. Kocha
{"title":"Pharmacotherapies for Behavioral and Psychological Symptomsof Dementia with AlzheimerâÂÂs Disease: Two Subcategories of theseSymptoms","authors":"K. Hori, Misa Hosoi, Kimiko Konishi, M. Hachisu, H. Tomioka, Michiho Sodenaga, Chiaki Hashimoto, Ouga Sasaki, Mioto Maedomari, Itsuku Suzuki, Masanori Tadokoro, Sachiko Tsukahara, Hiroyuki Kamatani, Masayuki Tani, Hiroaki Tanaka, Y. Kitajima, H. Kocha","doi":"10.4172/2168-975X.1000225","DOIUrl":null,"url":null,"abstract":"In this article, we reviewed our previous articles those showed that ageing process and disease progression connected affective disturbances and anxiety with delusion, hallucination and aggressiveness and those behavioral and psychological symptoms of dementia (BPSD) is related with bipolarity (BT), and we comment the pharmacotherapies for BPSD in Alzheimer’s disease (AD). There are two types of BPSD with AD. One is related with the progressions of AD that is caused by the deteriorated lesions by AD pathology. Therefore, these symptoms are ameliorated by the treatment for AD, that is, cholinesterase inhibitors or N-methyl-D-aspartate receptors antagonist. The other is related with brain reserve (BR) and cognitive reserve (CR). In this pattern, the information processing system is not deteriorated. However, low BR caused by BT and low CR modulate the behaviors etwas eccentric. When lowering of brain volume caused by AD pathology is added, i.e., BR is lower than before, BPSD appears. Therefore, in this patter, SSRI, atypical antipsychotics and anticonvulsants those have the treatment option for bipolar disorders, galanatmine and SNRI are needed.","PeriodicalId":9146,"journal":{"name":"Brain disorders & therapy","volume":"20 ","pages":"0-0"},"PeriodicalIF":0.0000,"publicationDate":"2016-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain disorders & therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2168-975X.1000225","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
In this article, we reviewed our previous articles those showed that ageing process and disease progression connected affective disturbances and anxiety with delusion, hallucination and aggressiveness and those behavioral and psychological symptoms of dementia (BPSD) is related with bipolarity (BT), and we comment the pharmacotherapies for BPSD in Alzheimer’s disease (AD). There are two types of BPSD with AD. One is related with the progressions of AD that is caused by the deteriorated lesions by AD pathology. Therefore, these symptoms are ameliorated by the treatment for AD, that is, cholinesterase inhibitors or N-methyl-D-aspartate receptors antagonist. The other is related with brain reserve (BR) and cognitive reserve (CR). In this pattern, the information processing system is not deteriorated. However, low BR caused by BT and low CR modulate the behaviors etwas eccentric. When lowering of brain volume caused by AD pathology is added, i.e., BR is lower than before, BPSD appears. Therefore, in this patter, SSRI, atypical antipsychotics and anticonvulsants those have the treatment option for bipolar disorders, galanatmine and SNRI are needed.
在本文中，我们回顾了前人关于衰老过程和疾病进展将情感障碍和焦虑与妄想、幻觉和攻击性联系起来的研究，以及老年痴呆症(BPSD)的行为和心理症状与双极性(BT)有关的研究，并对BPSD在老年痴呆症(AD)中的药物治疗进行了评述。有两种类型的BPSD与AD。一种与阿尔茨海默病的进展有关，这是由阿尔茨海默病病理引起的病变恶化引起的。因此，通过治疗AD，即胆碱酯酶抑制剂或n -甲基- d -天冬氨酸受体拮抗剂，这些症状得到改善。另一个与脑储备(BR)和认知储备(CR)有关。在这种模式下，信息处理系统不会恶化。然而，由BT和低CR引起的低BR对行为的调节是偏心的。当加上AD病理导致的脑容量降低，即脑容量比术前降低时，出现BPSD。因此，在这种情况下，需要使用SSRI、非典型抗精神病药和抗惊厥药(双相情感障碍的治疗选择)、galanatamine和SNRI。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
